公开(公告)号：JP2005126845A

公开(公告)日：2005-05-19

申请号：JP2003362918

申请日：2003-10-23

Applicant: Jia-Yan Lin ,  Jang-Ching Ma ,  林佳燕 ,  馬樟▲清▼

Inventor： MA JANG-CHING ,  LIN JIA-YAN

IPC: A42B3/28

Abstract: PROBLEM TO BE SOLVED: To obtain an air-permeable helmet having merits of being cool in summer and warm in winter by having an air stream control valve apparatus having air permeability.
SOLUTION: The air-permeable helmet is designed for both excellent heat radiation effect and moisture retaining effect by having an air stream control valve apparatus having air permeability. The valve is arranged on the top of the helmet and is opened and closed to regulate air flow. In summer, the valve is pushed forward, air in the helmet flows through a large hole toward a space above the valve and a rain cover so as to relieve humid heat in the helmet. In winter, the valve is moved backward, tightly fitted to the rain cover to close the inside of the helmet so that circulation of air in the helmet is blocked and vent holes at both sides of the helmet are closed. A heat insulation cover avoids inflow of cold air outside the helmet and keeps the inside of the helmet warm.
COPYRIGHT: (C)2005,JPO&NCIPI

Abstract translation: 要解决的问题：通过具有具有透气性的气流控制阀装置，获得在夏季和冬季温暖的优点的透气性头盔。 解决方案：透气头盔通过具有具有透气性的气流控制阀装置而被设计用于优异的散热效果和保湿效果。 阀门布置在头盔的顶部，打开和关闭以调节气流。 夏天，阀门向前推，头盔中的空气通过一个大孔朝向阀门上方的空间和雨罩流动，以减轻头盔中的潮湿的热量。 在冬天，阀门向后移动，紧紧地装在雨罩上，以封闭头盔的内部，使得头盔中的空气循环被堵塞，并且头盔两侧的通风孔关闭。 隔热罩可避免头盔外的冷气流入，并使头盔内部保持温暖。 版权所有（C）2005，JPO＆NCIPI

公开(公告)号：TWM588445U

公开(公告)日：2020-01-01

申请号：TW108212758

申请日：2019-09-26

Applicant: 賴彥霖 ,  LAI, YAN LIN ,  陳亞榆 ,  CHEN, YA YU

Inventor： 賴彥霖 ,  陳亞榆

IPC: A41D15/04

公开(公告)号：WO2022046747A1

公开(公告)日：2022-03-03

申请号：PCT/US2021/047313

申请日：2021-08-24

Applicant: MERCK SHARP & DOHME CORP. ,  FENG, Danqing ,  HUO, Pei ,  KEKEC, Ahmet ,  LIN, Songnian ,  PISSARNITSKI, Dmitri, A. ,  YAN, Lin

Inventor： FENG, Danqing ,  HUO, Pei ,  KEKEC, Ahmet ,  LIN, Songnian ,  PISSARNITSKI, Dmitri, A. ,  YAN, Lin

IPC: C07K14/62 ,  A61P3/10

Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.

公开(公告)号：WO2019125879A3

公开(公告)日：2019-06-27

申请号：PCT/US2018/065321

申请日：2018-12-13

Applicant: MERCK SHARP & DOHME CORP. ,  SMARTCELLS, INC. ,  YAN, Lin ,  HUO, Pei ,  KEKEC, Ahmet ,  ZHU, Yuping ,  PISSARNITSKI, Dmitri ,  FENG, Danqing, D. ,  MOYES, Chris ,  ZHAO, Zhiqiang ,  HUNTER, David, N. ,  LIN, Songnian ,  LANCASTER, Thomas, M. ,  CHEN, Benjamin

Inventor： YAN, Lin ,  HUO, Pei ,  KEKEC, Ahmet ,  ZHU, Yuping ,  PISSARNITSKI, Dmitri ,  FENG, Danqing, D. ,  MOYES, Chris ,  ZHAO, Zhiqiang ,  HUNTER, David, N. ,  LIN, Songnian ,  LANCASTER, Thomas, M. ,  CHEN, Benjamin

IPC: A61K31/70 ,  A61K38/28 ,  A61K47/50 ,  C07H15/02 ,  C07H15/04 ,  C07K14/62

Abstract: The present disclosure provides conjugates which comprise an insulin molecule conjugated via a conjugate framework to one or more separate ligands that include a first saccharide, and wherein the conjugate framework also comprises a fatty chain (e.g., a C8-30 fatty chain). In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.

公开(公告)号：WO2019125878A1

公开(公告)日：2019-06-27

申请号：PCT/US2018/065318

申请日：2018-12-13

Applicant: MERCK SHARP & DOHME CORP. ,  YAN, Lin ,  HUO, Pei ,  KEKEC, Ahmet ,  FENG, Danqing, D. ,  ZHU, Yuping ,  PISSARNITSKI, Dmitri ,  MOYES, Chris ,  LIN, Songnian

Inventor： YAN, Lin ,  HUO, Pei ,  KEKEC, Ahmet ,  FENG, Danqing, D. ,  ZHU, Yuping ,  PISSARNITSKI, Dmitri ,  MOYES, Chris ,  LIN, Songnian

IPC: A61K38/24 ,  A61K38/28 ,  A61K47/54 ,  C07K14/435 ,  C07K14/575 ,  C07K14/62

Abstract: The present disclosure provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands that each include a saccharide, wherein the framework, ligand, saccharide and insulin molecule optionally comprise a fatty chain (e.g., a C8-30 fatty chain), wherein when said insulin molecule is conjugated both to a C8-30 fatty chain and one or more separate ligands that each include a saccharide, said C8-30 fatty chain is linked to insulin molecule only, and wherein when the framework or ligand comprises a fatty chain the insulin molecule is conjugated to two or more separate ligands. In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.

公开(公告)号：WO2017189342A1

公开(公告)日：2017-11-02

申请号：PCT/US2017/028706

申请日：2017-04-21

Applicant: MERCK SHARP & DOHME CORP. ,  PALANI, Anandan ,  YANG, ZhiQiang ,  YAN, Lin ,  LIN, Songnian ,  HUO, Pei ,  NARGUND, Ravi

Inventor： PALANI, Anandan ,  YANG, ZhiQiang ,  YAN, Lin ,  LIN, Songnian ,  HUO, Pei ,  NARGUND, Ravi

IPC: A61K38/28 ,  A61K47/48 ,  A61P3/08

Abstract: Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.

Abstract translation: 公开了与具有至少一种肠降血糖素活性的肽缀合的胰岛素二聚体。

公开(公告)号：WO2015051052A2

公开(公告)日：2015-04-09

申请号：PCT/US2014/058714

申请日：2014-10-02

Applicant: MERCK SHARP & DOHME CORP. ,  LIN, Songnian ,  YAN, Lin ,  KEKEC, Ahmet ,  ZHU, Yuping ,  HUNTER, David, N. ,  HUO, Pei ,  FENG, Danqing ,  NARGUND, Ravi, P. ,  MOYES, Christopher, R. ,  ZHAO, Zhiqiang ,  PIPIK, Brenda ,  PISSARNITSKI, Dmitri ,  DUFFY, Joseph, L. ,  GUIDRY, Erin, N.

Inventor： LIN, Songnian ,  YAN, Lin ,  KEKEC, Ahmet ,  ZHU, Yuping ,  HUNTER, David, N. ,  HUO, Pei ,  FENG, Danqing ,  NARGUND, Ravi, P. ,  MOYES, Christopher, R. ,  ZHAO, Zhiqiang ,  PIPIK, Brenda ,  PISSARNITSKI, Dmitri ,  DUFFY, Joseph, L. ,  GUIDRY, Erin, N.

IPC: A61K47/48 ,  A61K38/28

CPC classification number: A61K47/61 ,  A61K38/28 ,  A61K47/549 ,  A61K47/64 ,  C07K14/62

Abstract: Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

Abstract translation: 胰岛素缀合物包含共价连接至具有两个臂的至少一个双齿连接体的胰岛素分子，每个臂独立地连接至包含糖的配体，并且其中连接体的至少一个配体是岩藻糖是 披露。 即使当给予有需要的受试者时，胰岛素缀合物显示响应于糖的系统浓度（例如葡萄糖或α-甲基甘露糖）的药代动力学（PK）和/或药效学（PD）曲线，所述受试者不存在外源性多价 糖结合分子如Con A。

公开(公告)号：WO2012151114A1

公开(公告)日：2012-11-08

申请号：PCT/US2012/035318

申请日：2012-04-27

Applicant: MERCK SHARP & DOHME CORP. ,  ALI, Amjad ,  LO, Michael, Man-Chu ,  YAN, Lin

Inventor： ALI, Amjad ,  LO, Michael, Man-Chu ,  YAN, Lin

IPC: A01N33/24 ,  A61K31/15 ,  C07C243/00

CPC classification number: C07C247/06 ,  C07B2200/07 ,  C07C245/24 ,  C07C291/08 ,  C07C2601/14 ,  C07D231/12 ,  C07D249/04 ,  C07D317/72

Abstract: The present invention includes diazeniumdiolate cyclohexyl derivatives, such as a compound having the structure of formula (I) wherein R 1 -R 13 are as defined herein, including various pharmaceutically acceptable salts and hydrates thereof, and pharmaceutical formulations comprising the diazeniumdiolate cyclohexyl derivatives. The invention also includes a method for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy, comprising administering a compounds of the invention to a patient having such a condition, or being at risk to having such condition.

Abstract translation: 本发明包括二氮烯二硫酸酯环己基衍生物，例如具有式（I）结构的化合物，其中R 1 -R 13如本文所定义，包括其各种药学上可接受的盐和水合物，以及包含二氮烯二硫酸环己基衍生物的药物制剂。 本发明还包括治疗高血压，肺动脉高压（PAH），充血性心力衰竭，过度保水，心血管疾病，糖尿病，氧化应激，内皮功能障碍，肝硬化，先兆子痫，骨质疏松症或肾病的病症的方法，包括 将具有这种病症或有风险患有这种病症的患者给予本发明的化合物。

公开(公告)号：WO2012142388A3

公开(公告)日：2012-10-18

申请号：PCT/US2012/033485

申请日：2012-04-13

Applicant: NEW YORK UNIVERSITY ,  STONE, Eric, A. ,  YAN, Lin ,  QUARTERMAIN, David ,  SARFRAZ, Yasmeen

Inventor： STONE, Eric, A. ,  YAN, Lin ,  QUARTERMAIN, David ,  SARFRAZ, Yasmeen

IPC: A61K31/137 ,  A61K31/13 ,  A61K31/138 ,  A61P25/24 ,  A61P25/00

Abstract: Pharmaceutical compositions containing a cocktail of inhibitors of central stress nuclei are provided. The pharmaceutical compositions are useful for the prevention and treatment of a variety of conditions in mammals including humans, including anxiety and mood disorders such as depression.

公开(公告)号：WO2008094473A1

公开(公告)日：2008-08-07

申请号：PCT/US2008/001033

申请日：2008-01-25

Applicant: MERCK & CO., INC. ,  DEBENHAM, John, S. ,  HALE, Jeffrey, J. ,  HUO, Pei ,  MADSEN-DUGGAN, Christina, B. ,  WALSH, Thomas, F. ,  YAN, Lin

Inventor： DEBENHAM, John, S. ,  HALE, Jeffrey, J. ,  HUO, Pei ,  MADSEN-DUGGAN, Christina, B. ,  WALSH, Thomas, F. ,  YAN, Lin

IPC: C07D491/052 ,  C07D491/107 ,  C07D491/113 ,  C07D495/20 ,  A61K31/436 ,  A61K31/4365 ,  A61P3/04 ,  A61P25/18 ,  A61P25/22 ,  A61P25/28

CPC classification number: C07D491/052 ,  C07D491/107 ,  C07D491/113 ,  C07D495/20

Abstract: Novel compounds of the structural Formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, Huntington's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Abstract translation: 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，阿尔茨海默病，偏头痛，神经病，包括多发性硬化症和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症的中枢作用药物 脑血管意外，头部创伤，焦虑障碍，压力，癫痫，帕金森病，亨廷顿病，运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。